Celiac disease onset after pegylated interferon and ribavirin treatment of chronic hepatitis C

Arquivos de Gastroenterologia

Elson V. Martins Jr.¹  Ana K. Gaburri¹ 

[1] ,Universidade Metropolitana de Santos Gastroenterology and Hepatology Section Division of Internal Medicine

关键词: Celiac disease;    Hepatitis C;    Interferon Alfa-2a;    Ribavirin;    Autoantibodies;    Doença celíaca;    Hepatite C;    Interferon alfa-2a;    Ribavirina;    Auto-anticorpos;   

DOI  :  10.1590/S0004-28032004000200012

来源: SciELO

【 摘 要 】

AIM: Report of a case of a woman patient who developed celiac disease after pegylated interferon alpha-2a and ribavirin use for chronic hepatitis C. PATIENT AND METHOD: A 34-year-old woman with chronic hepatitis C, genotype 3, receiving pegylated interferon alpha-2a and ribavirin for 6 months, developed progressive malaise and anemia 6 months after the end of treatment. RESULT: Additional investigation revealed duodenal villous atrophy and positivity for anti-endomysium and anti-gliadin antibodies. Celiac disease diagnosis was performed and symptoms and laboratory abnormalities improved after gluten-free diet. CONCLUSION: Celiac disease must be ruled out in patients with malabsorption complaints in or after interferon (or pegylated interferon) therapy. Screening for celiac disease with detection of anti-endomysium antibodies would be done in susceptible patients.

【 授权许可】

CC BY-NC   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License